

GLAXOSMITHKLINE PLC  
Form 6-K  
August 28, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending August 2013

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of the Connected Persons of a Director and of a Person Discharging Managerial Responsibility (PDMR), in Ordinary Shares and American Depositary Shares (ADSs) in GlaxoSmithKline plc, as a result of awards made under the GlaxoSmithKline 2009 Share Value Plan on 27 August 2013 as follows:

Director/PDMR	Connected Person	Ordinary Shares	ADSs
Mr P Thomson	Mrs K Thomson	2,076	
Dr M Slaoui*	Dr K Slaoui		2,990

\* Denotes an Executive Director

The closing middle market price of an Ordinary Share on 27 August 2013 was £16.77 and the closing middle market price of an ADS was \$51.76.

The Company and the above-mentioned individuals were advised of these transactions on 27 August 2013.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).

S M Bicknell  
Company Secretary

28 August 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 28, 2013

By: SIMON BICKNELL

-----

Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc